NUTLEY, NJ - Eisai, an oncology and neurology-focused pharmaceutical company, is the latest firm to call Prism's On3 campus home. The Japanese firm will occupy the iconic 15-story International style tower that anchors the life-science campus straddling the border of the Township of Nutley and City of Clifton.
Presently based in Woodcliff Lake NJ, the company will relocate its headquarters and up to 1200 corporate staff and research and development activities to Nutley by the end of 2021. Eisai joins other innovators on the life-sciences campus including Modern Meadow, Quest Diagnostics, and the Hackensack Meridian Health School of Medicine.
“Eisai is a human health care company. This ON3 Eisai workplace will bring the Eisai community together in one place and drive a culture of new scientific horizons and entrepreneurial innovation.” says Tatsuyuki Yasuno, President of Eisai Inc. “We draw inspiration from our patients and passion from our people. We break barriers every day. Our workplace will too.” Tokyo-based Eisai Co., Ltd., is a fully integrated pharmaceutical business that operates in two global business groups: oncology
and neurology (dementia-related diseases and neurodegenerative diseases).
On3 is the largest redevelopment project in the Garden State. The massive project utilizes creative urban planning to integrate office, retail, research, residential, and lodging on the site of the former headquarters of Roche pharmaceuticals.
“We are excited to welcome Eisai Inc. as the first biopharmaceutical company to this thriving center for
healthcare,” says Prism Capital Partners owner Eugene Diaz. Owner Edwin Cohen adds “Eisai brings exceptional scientific and business expertise to this ever-expanding center for New Jersey and global business in a lease that has brought the Campus to 100% occupancy.”
According to Prism, this state-of-the-art building and campus will ultimately bring all of Eisai’s New Jersey-based employees together in one place to foster extensive employee engagement and collaboration.
Eisai's U.S. headquarters, commercial and clinical development organizations are located in New Jersey. The company's discovery labs are in Massachusetts and Pennsylvania; and global demand chain organization resides in Maryland and
Eisai will fully occupy 200 Metro Boulevard, the campus’ flagship 15-story LEED Gold office tower.